` IPIX (Innovation Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

IPIX
vs
S&P 500

Over the past 12 months, IPIX has significantly outperformed S&P 500, delivering a return of +2 000% compared to the S&P 500's +17% growth.

Stocks Performance
IPIX vs S&P 500

Loading
IPIX
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
IPIX vs S&P 500

Performance Gap Between IPIX and GSPC
HIDDEN
Show

Performance By Year
IPIX vs S&P 500

Loading
IPIX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Innovation Pharmaceuticals Inc vs Peers

S&P 500
IPIX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Innovation Pharmaceuticals Inc
Glance View

Market Cap
1.1m USD
Industry
Biotechnology

Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company. The company is headquartered in Wakefield, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2007-04-02. The firm is engaged in developing therapies with anti-inflammatory, antibiotic, antiviral, dermatology and oncology applications. The firm owns the right to numerous drug compounds, including Brilacidin, its lead drug in a class of compounds known as defensin-mimetics and Kevetrin (thioureidobutyronitrile), which is its lead anti-cancer compound. The firm's clinical trials focused on evaluating its drug candidates, including Kevetrin for the treatment of cancers and Brilacidin for treatments of Acute Bacterial Skin and Skin Structure Infection (ABSSSI), prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative colitis. The firm is focused on developing small molecule therapies to treat diseases in the areas of inflammatory diseases, cancer, dermatology and anti-infectives.

IPIX Intrinsic Value
Not Available
Back to Top